This Frontotemporal dementia - Pipeline Insight, 2021 provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Frontotemporal dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Frontotemporal dementia (FTD) is a group of related conditions resulting from the progressive degeneration of the temporal and frontal lobes of the brain. These areas of the brain play a significant role in decision-making, behavioral control, emotion and language. The clinical symptoms of FTD are caused by degeneration in the parts of the brain that control decision-making, behavior, emotion and language (typically the frontal, temporal and insular regions). In people under age 60, FTD is the most common cause of dementia and affects as many people as Alzheimer's disease in the 45-64 age group.
Frontotemporal dementia - Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Frontotemporal dementia pipeline landscape is provided which includes the disease overview and Frontotemporal dementia treatment guidelines. The assessment part of the report embraces, in depth Frontotemporal dementia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Frontotemporal dementia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Frontotemporal dementia R&D. The therapies under development are focused on novel approaches to treat/improve Frontotemporal dementia.
This segment of the Frontotemporal dementia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
PR006: Prevail Therapeutics
PR006 is being developed as a potentially disease-modifying, single-dose gene therapy for patients with frontotemporal dementia with GRN mutations (FTD-GRN). PR006 is designed to slow or stop disease progression in FTD-GRN patients by increasing progranulin levels via delivery of a healthy GRN gene into the central nervous system (CNS). Like PR001, PR006 is administered by injection into the cisterna magna, using the well-studied viral vector AAV9. The U.S. FDA has granted Orphan Drug designation for the treatment of FTD and Fast Track designation for the treatment of FTD-GRN. The European Commission has granted orphan designation for PR006 for the treatment of FTD. PR006 is currently being studied in our PROCLAIM trial, a Phase I/II clinical trial of PR006 for the treatment of patients with FTD-GRN.
AL001: Alector
AL001, is a humanized recombinant monoclonal antibody that is intended to be delivered by intravenous, peripheral infusion to the bloodstream to increase the levels of PGRN in the brains of FTD-GRN patients. AL001 functions by shutting down the SORT1 degradation mechanism for PGRN and increasing the circulating half-life of the functional PGRN in the brain. AL001 received orphan drug designation from the FDA for the treatment of FTD in 2018. Currently, it is in phase III stage of development to treat Frontotemporal dementia.
There are approx. 20+ key companies which are developing the therapies for Frontotemporal dementia. The companies which have their Frontotemporal dementia drug candidates in the most advanced stage, i.e. phase III include, Alector.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Frontotemporal dementia therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Frontotemporal dementia drugs.
Geography Covered
- Global coverage
Frontotemporal dementia Understanding
Frontotemporal dementia: Overview
Frontotemporal dementia (FTD) is a group of related conditions resulting from the progressive degeneration of the temporal and frontal lobes of the brain. These areas of the brain play a significant role in decision-making, behavioral control, emotion and language. The clinical symptoms of FTD are caused by degeneration in the parts of the brain that control decision-making, behavior, emotion and language (typically the frontal, temporal and insular regions). In people under age 60, FTD is the most common cause of dementia and affects as many people as Alzheimer's disease in the 45-64 age group.
Frontotemporal dementia - Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Frontotemporal dementia pipeline landscape is provided which includes the disease overview and Frontotemporal dementia treatment guidelines. The assessment part of the report embraces, in depth Frontotemporal dementia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Frontotemporal dementia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Frontotemporal dementia R&D. The therapies under development are focused on novel approaches to treat/improve Frontotemporal dementia.
Frontotemporal dementia Emerging Drugs Chapters
This segment of the Frontotemporal dementia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Frontotemporal dementia Emerging Drugs
PR006: Prevail Therapeutics
PR006 is being developed as a potentially disease-modifying, single-dose gene therapy for patients with frontotemporal dementia with GRN mutations (FTD-GRN). PR006 is designed to slow or stop disease progression in FTD-GRN patients by increasing progranulin levels via delivery of a healthy GRN gene into the central nervous system (CNS). Like PR001, PR006 is administered by injection into the cisterna magna, using the well-studied viral vector AAV9. The U.S. FDA has granted Orphan Drug designation for the treatment of FTD and Fast Track designation for the treatment of FTD-GRN. The European Commission has granted orphan designation for PR006 for the treatment of FTD. PR006 is currently being studied in our PROCLAIM trial, a Phase I/II clinical trial of PR006 for the treatment of patients with FTD-GRN.
AL001: Alector
AL001, is a humanized recombinant monoclonal antibody that is intended to be delivered by intravenous, peripheral infusion to the bloodstream to increase the levels of PGRN in the brains of FTD-GRN patients. AL001 functions by shutting down the SORT1 degradation mechanism for PGRN and increasing the circulating half-life of the functional PGRN in the brain. AL001 received orphan drug designation from the FDA for the treatment of FTD in 2018. Currently, it is in phase III stage of development to treat Frontotemporal dementia.
Frontotemporal dementia: Therapeutic Assessment
This segment of the report provides insights about the different Frontotemporal dementia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Frontotemporal dementia
There are approx. 20+ key companies which are developing the therapies for Frontotemporal dementia. The companies which have their Frontotemporal dementia drug candidates in the most advanced stage, i.e. phase III include, Alector.
Phases
This report covers around 20+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Frontotemporal dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Frontotemporal dementia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Frontotemporal dementia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Frontotemporal dementia drugs.
Frontotemporal dementia Report Insights
- Frontotemporal dementia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Frontotemporal dementia Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Frontotemporal dementia drugs?
- How many Frontotemporal dementia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Frontotemporal dementia?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Frontotemporal dementia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Frontotemporal dementia and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Alector
- Prevail Therapeutics
- Passage Bio, Inc.
- TauRx Pharmaceuticals
- Wave Life Sciences Ltd.
- CAMP4 Therapeutics
- Coya Therapeutics
- SOLA Biosciences
- AcuraStem
- Denali Therapeutics
- Wave Life Sciences
- Neurimmune
- Biogen
- Asceneuron SA
- Libra Therapeutics
- Muna Therapeutics
- Alkermes
- DEEP GENOMICS
- Sangamo Therapeutics
- LOCANABIO
- Arkuda Therapeutics
- AZTherapies
- Yumanity
- Autifony Therapeutics
- Prothena
Key Products
- PR006
- AL 001
- PBFT02
- TRx-0237
- WVE-004
- EXO-050
- SOL 257
- AS 201
- AS 202
- DNL593
- NI308
- NI205
Table of Contents
IntroductionExecutive Summary
Frontotemporal dementia: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
- Comparative Analysis
AL001: Alector
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I/II)
- Comparative Analysis
PR006: Prevail Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
EXO-050: Coya Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Frontotemporal dementia Key Companies
Frontotemporal dementia Key Products
Frontotemporal dementia- Unmet Needs
Frontotemporal dementia- Market Drivers and Barriers
Frontotemporal dementia- Future Perspectives and Conclusion
Frontotemporal dementia Analyst Views
Frontotemporal dementia Key Companies
AppendixList of Tables
Table 1 Total Products for Frontotemporal dementia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Frontotemporal dementia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- AcuraStem
- Alector
- Alkermes
- Arkuda Therapeutics
- Asceneuron SA
- Autifony Therapeutics
- AZTherapies
- Biogen
- CAMP4 Therapeutics
- Coya Therapeutics
- DEEP GENOMICS
- Denali Therapeutics
- Libra Therapeutics
- LOCANABIO
- Muna Therapeutics
- Neurimmune
- Passage Bio, Inc.
- Prevail Therapeutics
- Prothena
- Sangamo Therapeutics
- SOLA Biosciences
- TauRx Pharmaceuticals
- Wave Life Sciences Ltd.
- Yumanity
